靶向GPX4棕榈酰化增强抗肿瘤免疫。

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-06-01 Epub Date: 2025-05-14 DOI:10.1016/j.trecan.2025.05.001

Daehee Hwang, Whitney S Henry

引用次数: 0

摘要

尽管癌症免疫治疗取得了重大进展，但肿瘤细胞经常逃避免疫监视。Zhou等人发现关键的铁下垂抑制因子谷胱甘肽过氧化物酶4 （GPX4）可被zDHHC8棕榈酰化，增强铁下垂抗性。本研究强调了靶向GPX4棕榈酰化以增强细胞毒性T细胞介导的肿瘤细胞铁下垂的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Targeting GPX4 palmitoylation to boost antitumor immunity.

Despite significant milestones in cancer immunotherapy, tumor cells often escape immune surveillance. Zhou et al. revealed that the pivotal ferroptosis suppressor glutathione peroxidase 4 (GPX4) can undergo palmitoylation by zDHHC8, enhancing ferroptosis resistance. This study highlights the potential of targeting GPX4 palmitoylation to enhance cytotoxic T cell-mediated ferroptosis of tumor cells.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.